FDA accepts AstraZeneca's fish oil-based drug Epanova for review

09/19/2013 | Reuters · PharmaTimes (U.K.)

The FDA has accepted AstraZeneca's application to market its fish oil-based drug Epanova as a treatment for severe hypertriglyceridemia. The drug was originally developed by Omthera Pharmaceuticals, which was bought by AstraZeneca this year. A decision is expected by May 5.

View Full Article in:

Reuters · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD